Opus Genetics, Inc. (IRD) Financial Ratios
6 years of historical data (2019–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
21.30
↑+350% vs avg
5yr avg: 4.73
30Y Low4.7·High4.7
ROE
↑
-203.2%
↓+45% vs avg
5yr avg: -366.7%
30Y Low-203%·High52%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IRD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Opus Genetics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $346M | $32M | — | — | — | — | — |
| Enterprise Value | $316M | $1M | — | — | — | — | — |
| P/E Ratio → | -2.49 | — | — | — | — | — | — |
| P/S Ratio | 31.47 | 2.89 | — | — | — | — | — |
| P/B Ratio | 21.30 | 4.73 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
IRD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.13 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
IRD Profitability
Margins and return-on-capital ratios measuring operating efficiency
Opus Genetics, Inc. earns an operating margin of -564.7%. Operating margins have compressed from 45.7% to -564.7% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -203.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — |
| Operating Margin | -564.7% | -564.7% | -55.5% | 45.7% | -3854.8% | — | — |
| Net Profit Margin | -523.4% | -523.4% | -52.4% | 44.9% | -9625.3% | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -203.2% | -203.2% | -20.8% | 52.3% | -1295.1% | — | — |
| ROA | -126.7% | -126.7% | -19.4% | 47.7% | -259.1% | -253.0% | -345.8% |
| ROIC | — | — | -526.4% | 1493.1% | — | — | — |
| ROCE | -164.5% | -164.5% | -22.0% | 53.2% | -123.7% | -575.7% | — |
IRD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $30M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.02 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -4.51 | -1.01 | -0.92 | -1.08 | — | — |
| Net Debt / EBITDA | — | — | — | -2.34 | — | — | — |
| Debt / FCF | — | — | — | -2.98 | — | — | — |
| Interest Coverage | — | — | -7.95 | 2025.11 | -11352.50 | -2.92 | -2.98 |
Net cash position: cash ($30M) exceeds total debt ($0)
IRD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Opus Genetics, Inc.'s current ratio of 3.24x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 17.79x to 3.24x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 3.24 | 3.24 | 13.35 | 17.79 | 6.76 | 5.55 | 0.19 |
| Quick Ratio | 3.24 | 3.24 | 13.35 | 17.79 | 6.76 | 5.55 | 0.19 |
| Cash Ratio | 2.68 | 2.68 | 12.50 | 15.50 | 6.42 | 5.15 | 0.16 |
| Asset Turnover | — | 0.30 | 0.35 | 0.81 | 0.02 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 191.66 | 44.70 | 44.42 | — | — | — |
IRD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Opus Genetics, Inc. returns 0.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.2% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.2% | — | — | — | — | — |
| Shares Outstanding | — | $27M | $22M | $21M | $15M | $5M | $7M |
Peer Comparison
Compare IRD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IRDYou | $346M | -2.5 | — | — | 100.0% | -564.7% | -203.2% | — | — |
 REPL | $266M | -1.1 | — | — | — | — | -62.6% | -51.9% | — |
 JANX | $878M | -7.9 | — | — | — | -1576.7% | -15.9% | -15.3% | — |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 ADVM | $96M | -0.7 | — | — | 100.0% | -13915.9% | -189.8% | -124.2% | — |
 RGNX | $527M | -2.3 | — | — | 59.7% | -280.0% | -79.5% | -53.8% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See IRD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IRD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IRD vs REPL
Side-by-side business, growth, and profitability comparison vs Replimune Group, Inc..
Start ComparisonIRD — Frequently Asked Questions
Quick answers to the most common questions about buying IRD stock.
What is Opus Genetics, Inc.'s P/E ratio?
Opus Genetics, Inc.'s current P/E ratio is -2.5x. This places it at the 50th percentile of its historical range.
What is Opus Genetics, Inc.'s ROE?
Opus Genetics, Inc.'s return on equity (ROE) is -203.2%. The historical average is -57.2%.
Is IRD stock overvalued?
Based on historical data, Opus Genetics, Inc. is trading at a P/E of -2.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Opus Genetics, Inc.'s profit margins?
Opus Genetics, Inc. has 100.0% gross margin and -564.7% operating margin.